How I treat patients with diffuse large B-cell lymphoma.

@article{Armitage2007HowIT,
  title={How I treat patients with diffuse large B-cell lymphoma.},
  author={James Olen Armitage},
  journal={Blood},
  year={2007},
  volume={110 1},
  pages={29-36}
}
The disease we now call diffuse large B-cell lymphoma has gone by many names in the past. These have included reticulum cell sarcoma,1 diffuse histiocytic lymphoma,2 and, more recently, diffuse mixed lymphoma, diffuse large cell lymphoma, or immunoblastic lymphoma—terms from the Working Formulation.3 Early studies of therapy for patients with diffuse large B-cell lymphoma contained some patients with aggressive T-cell lymphoma, as these were lumped together in the Working Formulation and some… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 59 extracted citations

Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives

Clinical & developmental immunology • 2010
View 6 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 83 references

Primary CNS lymphoma.

Expert review of anticancer therapy • 2007

Addition of rituximab to CHOP improves survival in the non-GCB subtype of diffuse large B-cell lymphoma [abstract

P Farinha, LH Sehn, BF Skinnider, JM Connors, RD. Gascoyne
Blood • 2006

BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2006

Similar Papers

Loading similar papers…